Anavex Life Sciences Corp (AVXL)

[end2war]

McMagyar

but to alleviate questions at the end, Anavex changed endpoint criteria to lessen possible caretaker possible bias.

My understanding from the supplemental PR issued today is that they changed the endpoints, not in December 21, but at the beginning when the trial was started.

I also now realize that the reference to discussions with the FDA about the endpoint change must have occurred a long time ago when they were planning the trial and trying to decide on the endpoints.

There is some confusion caused by AFs tweet, that focused on the timing of the CT.gov update, and brought the IBD story line to look at that. DR. Missling immediately tried to put out that fire with clarifications given to IBD. We don't know exactly what he told IBD, as we only know what they wrote.

It did clarify that he dealt completely with AF's issue. Today he is offering some supplemental information to tell more of the story so shareholders can see what has happened. I suggest that was necessary since the IBD story does not tell the full story.

It is up to you and others to figure out what he is saying. GLTY